Skip to main content

Klotho Options

Discover currently available options

Main categories for klotho therapies:

   Viral Gene Therapy
   Non-viral Gene Therapy (Plasmids/Minicircles)
   mRNA
   Injectable Proteins/Peptides/Small Molecules

Important Note:

All information below is from the public domain as of late 2025 or early 2026. Any errors are unintentional. This area is rapidly developing. If any information below is no longer relevant or accurate or you would like your information removed, please contact us and we will attend to it. Do not determine suitability based on any information from this website, which is for educational and informational purposes only; providing or listing information is not an endorsement or recommendation of any product or service. To our knowledge, none of these products have been approved by the FDA or any governing body. Please see your doctor before making any changes to lifestyle, supplements, or therapies.

Viral Gene Therapy 

Viral Vectors


What it is:

    • A viral vector (commonly Adeno-associated Virus - AAV) carrying a Klotho transgene that infects target cells to produce Klotho protein


How it works:

    • Viral vectors carry DNA encoding Klotho into target cells.
    • The viral capsid binds to cell-surface receptors, enters cells, and releases the DNA into the nucleus where the transgene exists predominantly as an episome (not integrated into the genome).
    • Cells then transcribe and translate the Klotho gene, secreting Klotho protein that acts locally or systemically.


Benefits:

    • Potential long-duration Klotho elevation from a single dose
    • Targeted delivery (serotypes for CNS, muscle, liver)
    • Strong preclinical efficacy


Risks & limitations:

    • Immune responses to capsid or transgene products; preexisting immunity can reduce effectiveness 
    • Insertional risks with integrating vectors (primarily lentivirus) and long‑term safety questions
    • Dose-related toxicities seen in some AAV programs
    • Typically single use only and non-repeatable due to anti-capsid immune responses
    • Long term monitoring for mutagenesis and immune reactions
    • Manufacturing complexity and high cost


Typical protocols & monitoring:

    • 6 months of Prednisone to reduce immune response
    • Intravenous (systemic), intramuscular (regional muscle targeting), or intrathecal
    • Monitor for immune reaction, immunologic monitoring (antibody titers) for 5-15 years.


How long it lasts:

    • Typical duration 2-5 years from a single administration, some estimated to endure 5-7 years but lack human data to confirm
    • Duration depends on vector, dose, target tissue and cell turnover, and immune response


Access & approximate cost:

    • Largely limited to clinical trials or company-sponsored programs 
    • Company example: Klotho Neurosciences (KLTO) developing AAV-based s-KL programs, Klothea Bio (AKL003 trials)  
    • Cost not commercially available. If ever FDA approved, single-dose AAV therapies can cost hundreds of thousands to >$1M in the U.S.
    • BioViva purported to offer AAV Klotho in Latin America for US$250,000
    • Triple Helix in 2025 offered AAV Klotho via IV for US$120,000
 immunologic monitoring (antibody titers)

Plasmids & Nano-Plasmids (Minicircles)

Non-viral. Non-Integrating. Does not alter DNA


What it is:

    • Delivery of DNA encoding Klotho to patient cells without viral vectors, instead using chemical or physical methods to enable host cells to produce Klotho protein
    • Standard plasmids have a bacterial backbone
    • Minicircle variants are plasmids which contain only the therapeutic expression cassette with the bacterial backbone removed for more efficient, longer expression compared to conventional plasmids. We will use the term "nano-plasmid" instead of minicircle to reduce confusion with the company named "Minicircle Inc" which purportedly uses plasmids with bacterial backbones rather than true minicircles. 


How it works:

    • Plasmid encoding Klotho is injected into the target tissue (commonly skeletal muscle such as the deltoid)
    • Cells take up the plasmid and translate Klotho - setting up a "Klotho factory" in the muscle, secreting Klotho into circulation


Benefits: 

    • No viral capsid - without risk of anti-caspid immunity, no need for prolonged monitoring
    • Localized delivery reduces systemic exposure if targeted to a specific tissue
    • Ability to repeat dosing on a schedule


Risks & limitations:

    • Expression is typically lower and less durable than some viral vectors
    • Providers using subcutaneous injections do not achieve prolonged benefits
 immunologic monitoring (antibody titers)

Available Plasmid/Nano-Plasmid Comparison

Comparison Table
Plasmid with PEI - Subcutaneous Injection
(i.e. "Minicircle Inc")
Nano-Plasmid with PEI - Intramuscular Injection
Nano-Plasmid Pure DNA - Electroporation
Plasmid Type & Method
  • Plasmid with backbone (supplied by the company "Minicircle Inc")
  • The DNA is complexed with PEI forming polyplexes that protect DNA and promote cell internalization
  • Subcutaneous adipose tissue acts as a protein-production depot releasing secreted Klotho into circulation
  • Nano-Plasmid (minicircles) without bacterial backbone
  • The DNA is complexed with PEI forming polyplexes that protect DNA and promote cell internalization
  • Once inside cells the plasmid reaches the nucleus and drives Klotho expression
  • Muscle fibers serve as sustained protein "factories"
  • Nano-Plasmid (minicircles) without bacterial backbone
  • Brief electrical pulses transiently open cell membranes, allowing DNA uptake and intracellular expression of KL protein
  • Muscle fibers serve as sustained protein "factories"
Main Benefit vs Other Plasmid Delivery Methods
  • Lowest cost to produce
  • Simple injection method without the need for specialized equipment
  • Nano-plasmid more durable than plasmids with the bacterial backbone
  • Intramuscular injection = longer duration than subcutaneous
  • Simple injection method without the need for specialized equipment
  • Pure nano-plasmid delivery without PEI or other agents
  • Higher expression and longer duration
  • Nano-plasmid more durable than plasmids with the bacterial backbone
  • Quick process completed in 15 minutes followed by 30 minute observation
Risks & Limitations
  • Plasmids with the bacterial backbone have lower expression and shorter duration than minicircles (which have the backbone removed)
  • PEI dosage unknown, large quantities can be cytotoxic and provoke inflammatory responses
  • Subcutaneous injection method lasts weeks to months
  • Very low risk of an inflammatory response with low dose PEI (100ug), but a 3-5 day course of low dose methyl-prednisone is recommended for optimal transfection
  • Intramuscular injection lasts longer than subcutaneous but less than other methods
  • Requires specialized equipment
  • Not recommended for use in clients with pacemakers or other electrical medical devices
Typical Protocols
  • Course of prednisone
  • Followed by subcutaneous injection and 30 minutes monitoring


  • 3-5 day course of low tapered dose of methylprednisone
  • Followed by DNA intramuscular injection and 30 minutes monitoring
  • Local anesthesia to the target muscle
  • Followed by DNA intramuscular injection
  • Then mild electrical pulses
How Long it Lasts
Several weeks to 6 months
12 months
18-24 months
Access & Approx. CostBy "Minicircle Inc" partner clinics in Latin America, Caribbean
Cost unknown, estimated to be US$50,000 		US$19,000-$30,000 in various locations in South East Asia
US$18,000-$25,000 in various locations in South East Asia

mRNA/LNP

Direct mRNA Therapy


What it is:

    • Synthetic, chemically modified mRNA encoding Klotho is delivered to patient cells so those cells transiently translate Klotho protein, producing rapid but short‑lived elevation of Klotho levels


How it works:

    • Synthetic mRNA carrying the Klotho coding sequence is delivered into the cytosol of target cells where ribosomes translate it into Klotho protein
    • Chemical modified nucleotides and optimized untranslated regions improve stability and reduce innate immune sensing
    • Protein expression decays as mRNA is degraded


Benefits:

    • Rapid onset of protein expression
    • mRNA does not enter the nucleus or integrate into DNA (safer genomic profile than AAV)
    • Repeatable dosing
    • Established platform used in vaccines


Risks & limitations:

    • Very transient expression (weeks to months) 
    • Innate immune activation possible
    • Requires effective delivery vehicle (LNPs are typical)
    • Repeated dosing required for sustained levels.


Typical protocols & monitoring:

    • Local (intramuscular, intradermal, local organ) or systemic (intravenous) injections
    • Often paired with lipid nanoparticles (LNPs) or other vehicle
    • Monitoring of systemic reactogenicity and labs
    • Dosing schedules depend on desired exposure 


How long it lasts:

    • Several weeks to months
    • Repeated dosing required for persistent elevation, typically every 3-6 months


Access & approximate cost:

    • Mostly preclinical for Klotho
    • mRNA therapeutics through research institutions or companies
    • Costs per dose vary, estimated tens of thousand dollars per dose
    • Potentially offered by Klothea Bio (ALK003 mRNA/LNP program), primarily trial-based
 immunologic monitoring (antibody titers)

Peptides, Klotho Protein & Small Molecules

Klotho Mimetics / Upregulators


What it is:

    • Klotho protein, or peptides derived from Klotho (e.g., Klotho peptide fragments) or small-molecule drugs that upregulate endogenous Klotho expression.
    • Albumin-Binding or MAB is engineered Klotho fused or bound to albumin domains to extend circulatory half‑life and reduce dosing frequency
    • Klotho-FG recombinant protein FG peptides refer to peptides that contain phenylalanine-glycine (FG) repeat sequences, often found in proteins that act as scaffolds or transporters within cells 


How it works:

    • Peptides can mimic Klotho activity by binding receptors or inhibiting pathways
    • Small molecules may increase Klotho transcription or stability
    • Klotho Protein elevates klotho levels during its short half life of approximately 6 hours
    • In Klotho-FG variants, PEGylation is a process in which a polyethylene glycol (PEG) molecule is attached to the Klotho peptide to improve transport and functionality within cells while ensuring that it can perform its specific function without interference from others


Benefits:

    • Injectable small-molecule/peptides/proteins are typically easier to dose-control
    • Lower initial cost to test effects of increased Klotho
    • Modified Albumin Binding (MAB) variants have longer duration and longer dosing intervals of 2 weeks
    • Klotho-FG variants have improved stability, half-life and circulation time compared to Klotho protein, and with a longer dosing interval of 3 times per week


Risks & limitations:

    • Peptides and proteins may have short half-lives and poor tissue penetration
    • Daily or frequent injections
    • Small molecules can have off-target effects
    • Variable evidence and quality
    • Some concern that Modified Albumin Binding (MAB) types may eventually lead to one's body rejecting their own natural klotho, this specific variant has not been shown to be effective for cognition or longevity as no testing data is currently available 


Typical protocols & monitoring:

    • Injectable dosing with standard clinical monitoring; labs, adverse-event surveillance 


How long it lasts:

    • Varies: small molecules/peptides typically require daily or periodic dosing
    • Modified Albumin Binding (MAB) variants purported to last up to 19 days
    • Klotho-FG variants last up to 2 days


Access & approximate cost:

    • Approximate price for Modified Albumin Binding (MAB) Klotho US$500/month via Biolongevity Labs with injections every 2 weeks
    • Approximate price for Klotho-FG recombinant protein US$1,800/month via Cecilia Lab with injections 3 times per week
    • Several other research grade products are available through research chemical companies such as Bucky Labs
 immunologic monitoring (antibody titers)